Form 4: ICU Medical CFO Brian Bonnell Reports Stock Transactions
SEC Form 4 Filing
Brian Bonnell, CFO of ICU Medical, reports the acquisition and disposal of common stock and restricted stock units on March 15, 2024.
Summary
- On March 15, 2024, Brian Bonnell, the Chief Financial Officer of ICU Medical Inc., reported transactions involving the company's stock.
- These transactions included the acquisition of 3,247 shares of common stock through the vesting of Restricted Stock Units (RSUs) and the disposal of 1,780 shares to cover tax obligations.
- The price per share for the disposed shares was $98.08.
- Following these transactions, Bonnell directly owns 24,954 shares of common stock and 6,496 derivative securities (Restricted Stock Units).
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations, with no clear positive or negative implications for the company's outlook.
Positives
- The vesting of RSUs indicates a form of compensation and alignment of the CFO's interests with the company's performance.
Negatives
- The disposal of shares could be perceived negatively, although it is likely related to covering tax obligations associated with the vesting of RSUs.
Risks
- There are no specific risks mentioned in this document, as it primarily reports stock transactions by an officer.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the financial industry to assess management's confidence in the company's prospects.
- Companies like Medtronic, Baxter International, and Becton Dickinson are also subject to similar insider trading regulations and reporting requirements.
- The disposal of shares to cover tax obligations is a standard practice among executives receiving equity compensation.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they represent routine insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/15/2023 | Date awards were legally granted but subject to shareholder approval. |
| 05/17/2023 | Date of shareholder approval for the awards. |
| 03/15/2024 | Date of the reported transactions: acquisition of stock via RSU vesting and disposal of stock. |
| 03/15/2026 | Expiration date of the derivative security. |
| 03/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.